A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial
A single intravenous dose of the psychedelic dimethyltryptamine, combined with psychological support, produces rapid and lasting reductions in depressive symptoms in adults with major depressive disorder.
